BEVACIZUMAB Teva conc perf 400 mg/16ml flac
7680678860026
CH-67886
L01FG01
07.16.1.
Reimbursement limitations:
BEVACIZU2.03
Carcinome rénal
Après accord sur la prise en charge des frais par l’assureur-maladie après consultation …
1 / 3
google
Details
- Product number
- 6788602
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- bevacizumabum 400 mg, trehalosum dihydricum, natrii dihydrogenophosphas monohydricus, dinatrii phosphas, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 16 ml corresp. natrium 21.76 mg.
Articles (1)
Bevacizumab-Teva 400 mg/16 ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
400.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
21.76 MG | Substance | HBESI |
Reimbursement information
Public price
CHF 1063.55
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/07/2021
Authorization holder
Teva Pharma AG
4051 Basel
Authorization information
- Swissmedic authorization number
- 67886
- Drug name
- Bevacizumab-Teva, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L01FG01
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 10/05/2021
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- BEVACIZUMAB Teva conc perf 400 mg/16ml flac
- Description (DE)
- BEVACIZUMAB Teva Inf Konz 400 mg/16ml Durchstf
- Market launch
- 10/05/2021
- Narcotic (BTM)
- No